Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04015622 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA

Study acronym: PROTRACT
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 20, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Apr 1, 2025 to Apr 1, 2026 Trial status: Recruiting to Active, Not Recruiting · Completion date: Dec 1, 2025 to Dec 1, 2026 · Site details revised at 7 of 7 sitesv18 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Dec 1, 2025 to Dec 1, 2026
    • Site details revised at 7 of 7 sites
  2. Study sites: 6 to 7v17
  3. Site details revised at 2 of 6 sitesv16
  4. Study sites: 5 to 6v15
  5. Study sites: 4 to 5v14
Show 12 earlier versionsHide 12 earlier versions
  1. Primary completion date: Dec 1, 2023 to Apr 1, 2025 Completion date: Dec 1, 2024 to Dec 1, 2025v13 Show 1 more changeShow less
    • Completion date: Dec 1, 2024 to Dec 1, 2025
  2. 2 versions Re-verified since Jul 11, 2022, no change to tracked fieldsv11-v12
  3. Site details revised at 1 of 4 sitesv10
  4. Eligibility criteria expanded, about 23 wordsv9 See this version in full on ClinicalTrials.gov ↗
  5. Re-verified, no change to tracked fieldsv8
  6. Study title shortened, about 2 wordsv7 See this version in full on ClinicalTrials.gov ↗
  7. Study sites: 5 to 4v6
  8. Site details revised at 1 of 5 sitesv5
  9. Trial status: Active, Not Recruiting to Recruiting Site details revised at 5 of 5 sitesv4 Show 1 more changeShow less
    • Site details revised at 5 of 5 sites
  10. Trial status: Not Yet Recruiting to Active, Not Recruiting Site contacts updated at 5 of 5 sitesv3 Show 1 more changeShow less
    • Site contacts updated at 5 of 5 sites
  11. Primary completion date: Dec 1, 2021 to Dec 1, 2023 Start date: Dec 1, 2019 to Oct 7, 2020 · Study sites: 0 to 5 · Completion date: Dec 1, 2022 to Dec 1, 2024 · 3 morev2 Show 6 more changesShow less
    • Start date: Dec 1, 2019 to Oct 7, 2020
    • Study sites: 0 to 5
    • Completion date: Dec 1, 2022 to Dec 1, 2024
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: 5 to 6
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the strategy in treatment selection using ctDNA fraction as a predictive biomarker to direct treatment decision (ctDNA fraction \<2% receives enzalutamide, and ctDNA fraction ≥2% receives docetaxel) versus clinician's choice of enzalutamide or docetaxel, in subjects with metastatic castration-resistant prostate cancer post abiraterone setting.
Trial Details
NCT Number NCT04015622
Lead Sponsor British Columbia Cancer Agency
Conditions Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov